Fibrinolysis and fibrinogenolysis treatment
AssigneeOrion Therapeutic Systems, Inc.
InventorsEdward Reich, Thomas G. Easton
Life of this patent
Estimating the term…
Abstract
Disclosed is a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active form at a concentration and for a time sufficient to permit fibrinolytically and fibrinogenolytically active human plasmin to reach a concentration about the site of an intravascular clot sufficient to lyse the clot and/or to reduce circulating fibrinogen levels.
Claims18
A fibrinolysis and fibrinogenolysis treatment comprising the step of:
- parenterally introducing into the body of a human patient in need thereof a therapeutically effective amount of human plasmin or mammalian mini- or micro-plasmin in fibrinolytically/fibrinogenolytically active form in an amount and for a time sufficient to permit said active plasmin to reach a concentration in the bloodstream of said patient sufficient to reduce the level of circulating fibrinogen, wherein, substantially coincident with parenteral introduction of said active plasmin into said patient, fibrinolytically/fibrinogenolytically plasminogen, or an analog thereof, or stabilized inhibited plasmin, is converted to said fibrinolytically/fibrinogenolytically active plasmin ex vivo.
A method of dissolving an intravascular thrombus in a human patient comprising administering parenterally to the patient a therapeutically effective amount of purified plasmin selected from the group consisting of miniplasmin, microplasmin, lys-plasmin, fibrinolytically active analogs thereof, and human plasmin, for a time and at a concentration sufficient to dissolve said thrombus, wherein, substantially coincident with said parenteral administration of said plasmin to said patient, fibrinolytically/fibrinogenolytically plasminogen, or an analog thereof, is converted to said plasmin ex vivo.
A method of reducing the risk of thrombus formation in a patient at risk for thrombus formation comprising administering parenterally to the patient a therapeutically effective amount of purified plasmin selected from the group consisting of miniplasmin, microplasmin, lys-plasmin, fibrinolytically active analogs thereof, and human plasmin, for a time and at a concentration sufficient to prevent the formation of a thrombus, wherein, substantially coincident with said parenteral administration of said plasmin to said patient, fibrinolytically/fibrinogenolytically plasminogen, or an analog thereof, is converted to said plasmin ex vivo.
Dependencies are inferred from the claim text.